Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a strategic partnership between its controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955), and Haier Biomedical. The collaboration will focus on the integration of digitalization, automation, and artificial intelligence (AI) to enhance the digital and innovative development within the pharmaceutical sector.
As per the agreement, Haier Biomedical will serve as a core strategic partner, tasked with upgrading its digital systems and developing customized digital solutions tailored to Boan Biotechnology’s requirements. This includes the implementation of EMS DataManager for data analysis, QC Sample Manager for sample management, EBR for electronic batch recording, and other key business processes. These advancements aim to elevate Boan Biotech’s manufacturing process and quality management to new digital heights. Concurrently, the partnership will harness the resource strengths of both companies to explore innovative avenues in the digital transformation of the pharmaceutical industry, leveraging digital analysis, automation, and AI integration. – Flcube.com
